And it’s a wrap! Stark Associates had a great time interacting with clients and business partners. We got great new leads to our near future prospects. We want to take a moment thank every client and business partner who took time to stop by our booth and interacted with our Client Services Representative, Madhukiran Parvathaneni. […]
USFDA has issued a final rule establishing the post-market safety reporting requirements specifically for combination products. These regulations for drugs, devices, and biological products share many similarities, however, each set of regulations has certain unique reporting requirements, standards and timeframes based in part on the characteristics of the type of product. The FDA’s new rule […]
According to ANVISA’s recent announcement, the new clinical data requirements apply to qualifying devices submitted for review in both cadastro and registro registration routes. The key points from the technical notefor manufacturers are: Clinical data is now required for all novel devices. Some high-risk devices for which ANVISA determines safety and effectiveness may only be demonstrated via clinical […]
The Malaysian MoH has published a guidance regarding the regulation of combination products that include both pharmaceutical and medical device components i.e., ‘drug-device’ combination. As per this guidance document, the combination product’s market registration pathway is as per its primary mode of action. Hence, the products with pharmaceutical primary actions would fall under the country’s National […]
The CFDA has announced the release of its “Principle of technical review of medical device software” (2015 Order No. 50). This Principle applies to both stand-alone software and software components that are either developed by medical device manufacturers or their design and development partners, including any Off-The Shelf (OTS) software as part of the stand-alone […]
The China FDA’s final rule on its priority review program for medical devices will come into force in January 2017. The CFDA’s final guidelineof the rule is open to Class III medical devices manufactured in China and Class II and III devices imported from foreign manufacturers. Chinese market registrants must apply for priority review qualification […]
The SFDA now regulates some borderline products as drugs rather than medical devices. The Saudi Arabian government has officially declared that it considers certain borderline products from medical device to be regulated as per pharmaceutical regulations according to a recent circular from the Saudi Food and Drug Authority (SFDA) The products identified below may no longer be […]
The CFDA has issued new requirements for Chinese market authorization applicants who need to submit hard and soft copies of their registration applications to CFDA. According to the CFDA announcement, Chinese market applicants with Class II and III devices will have to submit not only their original registration dossiers, but also photocopies and soft copies in […]
US Food and Drug Administration have notified labelers of some Class II devices that the deadline for Unique Device Identification (UDI) compliance has been extended to September 201.8. This extension affects three broad categories of devices, all of which now have a compliance date of September 24, 2018 for UDI labeling as well as Global Unique Device Identification […]